Key clinical point: Fixed-dose combination hypertension therapy has high rates of therapeutic inertia.
Major finding: Six-week FDC therapeutic inertia rates were 86.8% vs. 63.9% for usual care (P < .001).
Study details: Post hoc analysis of TRIUMPH randomized trial of 700 patients with hypertension in Sri Lanka from February 2016 to May 2017, with follow-up ending in October 2017.
Disclosures: Dr. Wang has no financial relationships to disclose. Study coauthors received funding from the Australian National Health and Medical Research Council and the U.K. National Institute for Health Research.
Wang N et al. JAMA Cardiol. 2020 Jul 22. doi: 10.1001/jamacardio.2020.2739